@article{10.4137/BCBCR.S14224, author={Adisorn Ratanaphan and Bhutorn Canyuk}, journal={Breast Cancer: Basic and Clinical Research}, publisher={Libertas Academica}, title={Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1}, year={2014}, month={03}, volume={8}, url={www.la-press.com/host-cell-reactivation-and-transcriptional-activation-of-carboplatin-m-article-a4131}, pages={51--56}, abstract={ The breast cancer susceptibility gene 1 (BRCA1) has been shown to maintain genomic stability through multiple functions in the regulation of DNA damage repair and transcription. Its translated BRCT (BRCA1 C-terminal domain) acts as a strong transcriptional activator. BRCA1 damaged by carboplatin treatment may lead to a loss of such functions. To address the possibility of the BRCA1 gene as a therapeutic target for carboplatin, we investigated the functional consequences of the 3′-terminal region of human BRCA1 following in vitro platination with carboplatin. A reduction in cellular BRCA1 repair of carboplatin-treated plasmid DNA, using a host cell reactivation assay, was dependent on the platination levels on the reporter gene. The transcriptional transactivation activity of the drug-modified BRCA1, assessed using a one-hybrid GAL4 transcriptional assay, was inversely proportional to the carboplatin doses. The data emphasized the potential of the BRCA1 gene to be a target for carboplatin treatment. }, doi={10.4137/BCBCR.S14224}, }